The v-myb oncogene of the avian myeloblastosis virus (AMV) is unique among known oncogenes in that it causes only acute leukemia in animals and transforms only hematopoietic cells in culture. AMV was discovered in the 1930s as a virus that caused a disease in chickens that is similar to acute myelogenous leukemia in humans (Hall et al., 1941) . This avian retrovirus played an important role in the history of cancer research for two reasons. First, AMV was used to demonstrate that all oncogenic viruses did not contain a single cancer-causing principle. In particular, although both Rous sarcoma virus (RSV) and AMV could replicate in cultures of either embryonic ®broblasts or hematopoietic cells, RSV could transform only ®broblasts whereas AMV could transform only hematopoietic cells (Baluda, 1963; Durban and Boettiger, 1981a) . Second, chickens infected with AMV develop remarkably high white counts and therefore their peripheral blood contains remarkably large quantities of viral particles (Beard, 1963) . For this reason AMV was often used as a prototypic retrovirus in order to study viral assembly and later to produce large amounts of reverse transcriptase for both research and commercial purposes.
Following the discovery of the v-src oncogene of RSV and the demonstration that it arose from the normal csrc proto-oncogene, a number of acute leukemia viruses were analysed by similar techniques and found to also contain viral oncogenes of cellular origin (Roussel et al., 1979) . In the case of AMV, it was shown that almost the entire retroviral env gene had been replaced by a sequence of cellular origin (initially called mab or amv, but later renamed v-myb) (Duesberg et al., 1980; Souza et al., 1980) . Remarkably, sequences contained in this myb oncogene were shared between AMV and the avian E26 leukemia virus, but were not contained in any other acutely transforming retroviruses. In addition, the E26 virus contained a second sequence of cellular origin (ets) that was unique. The E26 leukemia virus was ®rst described in the 1960s and causes an acute erythroblastosis in chickens, more reminiscent of the disease caused by avian erythroblastosis virus (AEV) than by AMV (Ivanov et al., 1962) .
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The viruses
Molecular cloning and DNA sequencing revealed that AMV contains an internal subset of the exons that encode c-Myb, as well as a portion of a c-myb intron that lies 5' of the ®rst exon contained in v-myb (Klempnauer et al., 1982; Rushlow et al., 1982; Souza et al., 1980) . These results imply that the 5' viral/ cellular recombination event that generated AMV occurred at the DNA rather than the RNA level . In addition, an inframe termination codon occurs just 5' of the splice acceptor site for the ®rst captured exon. As a result, the 48 kDa-v-Myb protein is produced by a subgenomic spliced viral mRNA that fuses the ®rst six codons of the gag gene in-frame to 371 codons of vmyb (Boyle et al., 1983; . The 3' cellular/viral recombination event occurred within an exon of c-myb, resulting in a fusion of the last eleven codons of the env gene in-frame with v-myb. A comparison of v-myb with c-myb cDNA sequences revealed that the v-Myb protein lacks 71 amino acids at its amino terminus and 199 amino acids at its carboxyl terminus relative to c-Myb (Gerondakis and Bishop, 1986; Rosson and Reddy, 1986) . In addition, v-Myb contains ten amino acid substitutions in the region shared with c-Myb (note that a putative 3'-most, eleventh substitution found by comparison with a cmyb genomic clone was also found in the two published c-myb cDNAs). These substitutions can strongly aect the phenotype of the transformed cells (Dini et al., 1995; Introna et al., 1990) .
Because AMV lacks almost the entire env gene and also the 3' portion of the pol open reading frame that overlaps the env open reading frame, this virus is defective for replication (reviewed in Baluda and Reddy, 1994) . Stocks of AMV that were passaged in chickens for many years and selected for leukemogenicity contained two helper viruses, MAV-1 (subgroup A) and MAV-2 (subgroup B). Molecular cloning of these helper viruses demonstrated that AMV almost certainly arose by recombination with MAV-1 (Perbal et al., 1985) . However, cell culture studies have shown that subgroup B rather than subgroup A viruses are most ecient at infecting the hematopoietic cells that are transformed by AMV .
Nevertheless, subgroup A viruses have generally been used in transformation assays with molecular clones of AMV because of their ability to replicate in quail cells, which can be infected by subgroup A but not B viruses and which lack endogenous retroviruses related to AMV and RSV (Lipsick and Ibanez, 1987; Moscovici et al., 1977) .
A remarkable feature of the AMV/MAV viral complex is that the U3 region of the long terminal repeats (LTRs) of these viruses is unrelated to that of all other known avian retroviruses (Bizub et al., 1984; Rushlow et al., 1982) . Although AMV-like viruses containing RSV LTRs can transform the same type of hematopoietic cells in culture, they are considerably less ecient (Engelke and Lipsick, 1994; Press et al., 1992) . Interestingly, the MAV helper virus alone causes nephroblastomas, a cancer rarely caused by the oncogene-de®cient Rous-associated viruses (RAVs) that contain an LTR similar to those of all other chicken retroviruses including the known endogenous viruses. Presumably, the reason for these biological dierences is that the viral U3 region contains the enhancer and promoter that regulate viral transcription. The unusual MAV LTR appears to have arisen very recently during evolution, possibly by a recombination event within a single diseased animal. In this regard, it is interesting to note that AMV was initially isolated from a chicken with Marek's disease, a T cell lymphoma caused by an avian herpes virus. Intriguingly, at least one T cell line isolated from a Marek's virus-infected chicken also contains a retroviral insertion in the c-myb locus (Le Rouzic and Perbal, 1996) . These results raise the possibility that the unusual AMV/MAV LTR may have arisen by recombination with Marek's disease virus rather than cellular DNA.
The E26 leukemia virus lacks much of the gag gene and all of the pol and env sequences. These viral sequences have been replaced by fragments of two dierent cellular genes, c-myb and c-ets (Leprince et al., 1983; Nunn et al., 1984) . As a result, the virus encodes a single 135 kDa Gag-Myb-Ets fusion protein. The cmyb and c-ets proto-oncogenes are present on two dierent chicken chromosomes, implying that either two successive recombinations with cellular DNA occurred or that the virus captured a pre-existing chromosomal translocation (Symonds et al., 1984b) . The portion of c-Myb encoded by the E26 virus is a subset of that encoded by AMV (Nunn et al., 1984) . In addition, v-Myb of E26 contains only a single amino acid substitution relative to c-Myb that diers from all of those present in v-Myb of AMV. Although the v-ets gene alone is weakly oncogenic at best when encoded by a retrovirus (Metz and Graf, 1991b) , retroviral insertions into ets-related genes have been observed in murine leukemias and chromosomal translocations involving ets-related genes have been observed in human cancers (reviewed in Graves and Petersen, 1998) . Remarkably, avian retroviruses that separately encode the v-Myb and v-Ets proteins of E26 undergo a strong selection in vivo for rearrangements that encode a Gag-Myb-Ets fusion protein (Metz and Graf, 1991a) .
The proteins (Figure 1) The 48 kDa v-Myb protein encoded by AMV, the 135 kDa Gag-Myb-Ets protein encoded by the E26 virus, and the 75 kDa c-Myb protein are all nuclear and bind to the same DNA sequence (AACNG) (Biedenkapp et al., 1988; Boyle et al., 1983 Boyle et al., , 1984 Klempnauer et al., , 1984 Klempnauer and Sippel, 1987) . The sequence that de®nes the Myb family of proteins is an approximately 50 amino acid motif with a series of conserved residues including three tryptophans separated by a characteristic spacing (reviewed in Lipsick, 1996) . This motif is present in three tandem repeats in c-Myb, the ®rst of which is drastically truncated in the AMV and E26 oncoproteins. Each repeat assumes a helix ± turn ± helix structure similar to that present in the bacterial repressor proteins and the eukaryotic homeodomains (Ogata et al., 1992 (Ogata et al., , 1994 . The second and third Myb repeats of c-Myb are together required for sequencespeci®c DNA-binding. The third helix of each of these repeats ®ts into the major groove of the DNA doublehelix to allow base-speci®c recognition. The Myb proteins themselves bind to DNA as monomers (Garcia et al., 1991; Howe et al., 1990) . Myb repeats have also been found in telomere-binding proteins and in non-DNA-binding transcriptional regulators (reviewed in Ganter and Lipsick, 1999) .
Two regions have been implicated in the nuclear localization of the v-Myb protein . First, a series of deletion mutants established that a sequence motif contained in the ®rst full Myb repeat (homologous to the second repeat of c-Myb) is required for nuclear localization. Second, a more carboxyl terminal sequence motif was required for ecient retention within the nucleus during biochemical fractionation. Presumably this second motif is required for protein-protein interactions that stabilize v-Myb within the nucleus. It has been reported that when v-Myb-transformed cells are induced to differentiate by treatment with phorbol ester (TPA), the vMyb protein is no longer nuclear (Klempnauer et al., 1984) . However, these results are dicult to reconcile with the observation that transcriptional activation by v-Myb is actually increased following such differentiation (Ganter et al., 1998) .
A v-Myb-like deletion of the amino terminus of cMyb including most of the ®rst Myb repeat converts a very weakly transforming c-Myb protein into an ecient oncoprotein . This deletion causes a decreased anity for DNA binding and also permits cyclin D to inhibit transcriptional activation in a CDK-independent fashion (Dini and Lipsick, 1993; Ganter et al., 1998) . The importance of this deletion in oncogenesis is underscored by the high frequency with which a similar deletion occurs in murine leukemia virus-induced myeloid malignancies in mice (reviewed in Shen-Ong, 1990 ). In addition to the absence of much of the ®rst Myb repeat, v-Myb also lacks an amino terminal casein kinase II (CKII) phosphorylation site at residues 11 and 12 of c-Myb (Luscher et al., 1989) and an adjacent stretch of acidic residues. However, mutagenesis of this CKII site in cMyb does not cause ecient oncogenic transformation in cell culture or cancer in animals (Dini and Lipsick, Figure 1 v-Myb and c-Myb proteins. Lightly shaded boxes, Myb repeats. Darkly shaded boxes, acidic region. Small arrows, amino acid substitutions in v-Myb. Striped boxes, Gag-and Ets-encoded residues. P, phosphorylation site. HLR, heptad leucine repeat. Ex 9A, insertion site of c-Myb exon 9A-encoded residues 1993; Jiang et al., 1997) . Retroviral insertional mutagenesis that results in a truncation of amino acids 1 ± 20 of c-Myb has been found in non-bursal B cell lymphomas caused by ALV in chickens (Kanter et al., 1988) . A recombinant retrovirus that encodes such a truncated protein causes lymphomas, sarcomas, and epithelial carcinomas in animals (Jiang et al., 1997) . These results suggest that the residues amino terminal to the ®rst Myb repeat are also critical for proper regulation of c-Myb. Furthermore, these residues may regulate a cell type-speci®c function of c-Myb. Four amino acid substitutions are present within the DNAbinding domain of AMV v-Myb, but not c-Myb or E26 Gag-Myb-Ets. These substitutions do not appear to alter the sequence speci®city of DNA-binding (Weston, 1992) , but do aect the ability of the protein to transform dierent cell types, to regulate speci®c genes, and to be regulated by other cellular proteins (Dini et al., 1995; Introna et al., 1990; Leverson and Ness, 1998) . Consistent with these observations, the biologically interesting substitutions occur on the surface of the protein that faces away from the DNA (Ogata et al., 1994) .
The central region of both v-Myb and c-Myb contain a transcriptional activation domain Sakura et al., 1989; Weston and Bishop, 1989) . This activation domain can function with heterologous DNA-binding domains such as that of the budding yeast GAL4 protein and the E. coli LexA protein (Dubendor et al., 1992; Kalkbrenner et al., 1990) . The sequences necessary for transcriptional activation by v-Myb were initially mapped to a small acidic region using GAL4-fusion proteins (Weston and Bishop, 1989) . However, in the context of v-Myb itself this region is not sucient for transcriptional activation (Bortner and Ostrowski, 1991; Ibanez and Lipsick, 1990) . Rather, a series of adjacent subdomains are required for transcriptional activation by v-Myb, including a sequence at its carboxyl terminus that includes a heptad leucine repeat and a conserved FAETL motif (Chen et al., 1995; Fu and Lipsick, 1996) . Interestingly, the amino acid substitutions accumulated during the passage and selection of AMV signi®cantly reduce transcriptional activation (Dini et al., 1995) . Furthermore, the v-Myb protein can activate the expression of some genes even in the absence of Myb-binding sites within the target gene Klempnauer et al., 1989) .
Carboxy-terminal to the minimal central activation domain of v-Myb lies a heptad leucine repeat that has also been referred to as the`leucine zipper'. In the context of full-length c-Myb, mutations in this region can activate the protein for both transcriptional regulation and for oncogenic transformation (KaneiIshii et al., 1992) . These results suggest that this region of the protein serves a negative regulatory function. A cellular protein, p160, that binds to this region has recently been isolated (Favier and Gonda, 1994; Tavner et al., 1998) . However, the same region appears to serve a positive regulatory function in vMyb because it is required for both transcriptional activation and oncogenic transformation (Bartunek et al., 1997; Fu and Lipsick, 1996) . In the latter case, it is not the leucine residues that are essential, but rather à FAETL' domain that is more highly conserved among all c-Myb and A-Myb proteins than the leucines. This region of c-Myb is absent in the E26 Gag-Myb-Ets proteins and v-Myb-like proteins with a similar deletion are only very weakly transforming . However, the addition of Ets sequences to such a protein restores transformation, arguing that Ets can substitute for the function of the heptad leucine repeat/FAETL domain (Fu and Lipsick, 1996) . Other oncogenes can also complement E26 Myb in trans in the absence of Ets (Metz et al., 1991) .
The carboxyl terminus of c-Myb that is absent in AMV v-Myb can negatively regulate transcriptional activation in animal cells (Sakura et al., 1989; Kalkbrenner et al., 1990) , but not in yeast (Chen and Lipsick, 1993; Seneca et al., 1993) . This negative regulation can also operate in animal cells with heterologous DNA-binding domains and in trans to the Myb transcriptional activation domain (Dubendor et al., 1992) . These results imply that an additional cellular protein absent in yeast is required for negative regulation of transcriptional activation by the carboxyl terminus of c-Myb. Several motifs in this region of the protein have been highly conserved in vertebrate c-Myb, A-Myb, B-Myb and in Drosophila Myb (Ganter and Lipsick, 1999 ). An adenovirus E1A-associated protein, BS69, has recently been shown to bind to this region of c-Myb and inhibit transcriptional activation (Hateboer et al., 1995) (Ladendor and Lipsick, unpublished) .
The carboxyl terminus of c-Myb has also been reported to inhibit DNA binding by c-Myb Tanaka et al., 1997) . In support of this model, the amino and carboxyl termini of c-Myb have been shown to interact in yeast two-hybrid assays and in bacterial phage display (Dash et al., 1996; Kiewitz and Wolfes, 1997) . Furthermore, another cellular protein, p100, that contains an`EVES' motif similar to that found in the carboxyl terminus of c-Myb has been proposed to regulate c-Myb function by competing with the carboxyl terminus for binding to the amino terminus (Dash et al., 1996) .
Cells and transformation assays (Figure 2)
AMV causes rapidly fatal monoblastic leukemia when injected into newly hatched chicks. This property was developed into an end-point titration assay and hundreds of thousands of chickens were used to purify and study the virus (reviewed in Beard, 1963) . Following the introduction of a cell culture assay for RSV by Rubin and Temin, similar assays were developed for AMV (Baluda and Goetz, 1961) . Unlike RSV and most other acutely transforming retroviruses, AMV does not transform ®broblasts in culture. Therefore assays were developed using dierent chicken tissues that are rich in hematopoietic cells. In the simplest form of the assay, non-adherent cells from embryonic yolk sac (days 12 ± 13), embryonic spleen (day 15), bone marrow, or peripheral blood are incubated with virus. During the course of a 2-week incubation, the immature progenitor cells will differentiate in culture into mature cell types. However, if AMV is present there will be a robust outgrowth of small round, highly refractile cells that are indistinguishable from the monoblasts present in the periph-eral blood of leukemic animals. This`liquid culture' assay remains the most sensitive method for the detection of weakly transforming viruses.
This assay can also be used as a quantitative tool by end-point dilution using multiple cultures, but two more useful quantitative assays have been developed for studying transformation by AMV. In the focus assay, embryonic yolk sac cells are permitted to dierentiate into a monolayer of adherent macrophages. This monolayer is then inoculated with virus and an agar overlay is used to restrict further diusion of the virus and cells. Foci of transformation are scored as bursts of round, rapidly growing cells arising from the monolayer . In the colony-forming assay, non-adherent hematopoietic precursor cells are incubated with virus and then seeded directly into soft agar or methyl cellulose . The formation of colonies within the semi-solid media can then be enumerated after 2 ± 3 weeks. Colony formation in soft agar is a more stringent assay of transformation by mutants of AMV because normal colonies are never observed in agar, but do occur in methyl cellulose. The advantages of methyl cellulose are that colony morphology can be more informative and individual colonies can easily be recovered by plucking and chilling, which liqui®es the methyl cellulose.
Once cell culture assays were developed for the acute leukemia viruses, a great deal of eort was directed at the question of whether dierent viruses transformed dierent`target' cells Graf et al., 1981) . It is now clear that AMV-transformed cells most closely resemble monoblasts, rapidly dividing progenitors that are committed to dierentiate into monocytes and macrophages (McNagny and Graf, 1996; Moscovici, 1985) . In this regard, AMV-transformed cells can be induced to dierentiate into macrophages by the addition of phorbol esters, activators of protein kinase C, despite the continued presence of the vMyb protein (Pessano et al., 1979; Symonds et al., 1984a) . Furthermore, although AMV-transformed cells are not very responsive to retinoic acid, the introduction of exogenous retinoic acid receptor causes these cells to dierentiate into macrophage-like cells in response to retinoids (Smarda et al., 1995; Zemanov and Smarda, 1998) . These results stand in contrast to studies with bipotential human HL60 leukemia cells that dierentiate into macrophages in response to phorbol esters and granulocytes in response to retinoids (Breitman et al., 1980) . Remarkably, cells at dierent stages of the monocytic lineage including what appear to be terminally dierentiated macrophages can be infected with AMV and be transformed into monoblasts (Boettiger and Durban, 1984; Durban and Boettiger, 1981b) . These results argue that AMVv-Myb can reverse a dierentiated phenotype.
Transformation assays of molecular clones of v-myb and c-myb were complicated by the failure of these genes to transform ®broblasts and the inability to transfect DNA eciently into primary hematopoietic cells. These problems were circumvented using a twostep assay in which a defective provirus co-expressing a dominant selectable marker (neo) is transfected into avian ®broblasts together with a replication-competent helper' provirus (Lipsick and Ibanez, 1987; Lipsick et al., 1986) . Following marker selection, the virusproducing ®broblasts are treated with mitomycin C to prevent cell division but not viral replication. These cells are then used as a`feeder layer' for the ecient transfer of the retrovirus into co-cultured nonadherent hematopoietic cells. One day later the nonadherent cells are then removed and used in either a liquid culture transformation assay or a colonyforming assay. More recently a variation of this assay has been described using a replication-competent version of AMV which expresses a gag, pol, env, and a myb gene (Press et al., 1992) . A temperaturesensitive variant of AMV has been isolated and molecularly characterized, but has proven dicult to use in experiments directed at understanding the mechanism of transformation by v-Myb Schirm et al., 1990) . In addition, viruses that produce estrogen-regulated forms of vMyb have been described (Burk and Klempnauer, 1991; Engelke et al., 1997) . These viruses cause estrogen-inducible morphological changes in a vMyc-transformed cell line, but are only weakly transforming in cultures of primary cells. Nevertheless, such viruses have proven useful for identifying genes that can be directly regulated by v-Myb .
The transformation assays for molecular clones of vmyb have been used to ask which features of the vMyb protein are required for biological activity. Nuclear transport, DNA binding, an essential cysteine within the DNA-binding domain, and another function provided by the carboxy terminal region of v-Myb appear to be required for oncogenic transformation Lane et al., 1990) . Similar assays were used to determine which alterations of c-myb induced by AMV are required for ecient oncogenic transformation. In brief, neither the gag nor env-encoded termini of v-Myb are required for transformation Lipsick and Ibanez, 1987) . The ten amino acid substitutions within v-Myb are also not required for transformation, but do aect the phenotype of the transformed cells (Stober- . In particular, reversion of individual substitutions within the DNA-binding domain cause the transformation of promyelocytes (granulocyte precursors) rather than monoblasts when assays are performed in the presence of cMGF, a chicken cytokine most similar to mammalian G-CSF (Introna et al., 1990) . However, substitutions in both the DNAbinding domain and the transcriptional activation domain are both required in order to cause a full AMV-like phenotype in which monoblasts are rapidly growing, have cell surface markers of the monocytic but not the granulocytic lineage, and are independent of exogenous growth factor by virtue of an autorcine loop (Dini et al., 1995) .
Deletion of the amino and/or carboxyl termini of cMyb is required for ecient transformation of myelomonocytic cells in culture . Truncation of both termini of c-Myb similar to that of v-Myb causes the most robust transformation. Truncation of the amino terminus alone is strongly transforming, whereas truncation of the carboxyl terminus alone is weakly transforming. The single truncations were initially reported to transform only promyelocytes in the presence of exogenous cMGF. However, in the absence of this cytokine the transformed cells appear to be bipotential myelomonoblasts that continue to dierentiate in culture (Wang and Lipsick, unpublished) . Full-length c-Myb causes a much weaker outgrowth of similar bipotential cells (Ferrao et al., 1995; Fu and Lipsick, 1997) .
Similar transformation assays have been developed for the E26 virus . Although the leukemia induced by this virus in chickens appears to consist primarily of immature erythroblasts, cell culture studies showed that both erythroid and myeloid cells could be transformed (Radke et al., 1982) . Further studies revealed the multipotential nature of these transformed progenitor cells Moscovici et al., 1983a,b) . Cell lines derived from these E26-transformed progenitors have proven very useful in dissecting the regulation of hematopoietic dierentiation (Kulessa et al., 1995; Rossi et al., 1996) . Temperature-sensitive variants of the E26 virus have been isolated and molecularly characterized (Beug et al., 1984) . Interestingly, a Gag-Myb-Ets protein with a substitution in the Myb DNA-binding domain is ts for transformation of myelomonocytic cells, whereas a mutant with a substitution in the Ets domain is ts for transformation of erythroid cells (Frykberg et al., 1988; Golay et al., 1988) . Unlike AMV, the E26 virus has also been reported to stimulate mitogenesis of ®broblasts in culture (Ravel-Chapuis et al., 1991) .
A murine assay for transformation by mutants of cMyb has been developed using fetal liver cultures in colony-forming assays (Gonda et al., 1989a) . In addition, a number of cell lines that are transformed by various Myb variants have been derived from such cultures (Gonda et al., 1989b) . In general, this fetal liver assay system has given results similar to those in the avian yolk sac and bone marrow assays described above with regard to activation by carboxy-terminal truncation of c-Myb (Hu et al., 1991) . Somewhat unexpectedly, the transformation of murine bone marrow cells with Myb viruses has not generally been successful. Although retroviral insertion into the c-myb locus is commonly found in murine leukemia virusinduced myeloid malignancies in mice (Shen-Ong et al., 1984; Shen-Ong and Wol, 1987) , infection of mice with Myb viruses has not been reported to cause disease. In addition, the productive infection of bone marrow cells or whole mice carrying a transgene that encodes the quail receptor for subgroup A avian retroviruses with AMV-related viruses does not cause leukemic transformation (Woo and Lipsick, unpublished) . These results suggest that mouse hematopoietic cells are more refractory to transformation by Myb proteins than are chicken cells, a ®nding that is similar to studies with v-Myc (Brightman et al., 1986) . However, v-Myb can cause long-latency T cell lymphomas in mice when produced by a T cell-specific transgene (Badiani et al., 1996) .
The mechanisms of oncogenic transformation
As is the case for other nuclear oncoproteins, the precise mechanism of transformation by v-Myb remains unclear. Two major questions to be addressed for v-Myb transformation are cell type-speci®city and the relationship between transcriptional regulation and oncogenic transformation.
The c-myb gene is normally expressed in all immature cells of the hemato-lymphoid system and this expression declines rapidly as the cells undergo terminal dierentiation (Chen, 1980; Duprey and Boettiger, 1985; Westin et al., 1982) . Consistent with this expression pattern, a homozygous disruption of cmyb in the laboratory mouse causes death in utero at day 15 with a dramatic failure of fetal liver erythroand myelopoiesis (Mucenski et al., 1991) . Interestingly, the earlier extra-embryonic yolk sac hematopoiesis appears normal in these mice. The production of exogenous c-Myb can block the dierentiation of cell lines that can otherwise be induced to dierentiate into erythrocytes or myelomonocytic cells (Clarke et al., 1988; Patel et al., 1993; Selvakumaran et al., 1992; Smarda and Lipsick, 1994; Todokoro et al., 1988) . Together these results had implied that the hematopoietic speci®city of AMV and E26 may be due to a similar speci®city of action of the c-myb protooncogene in regulating the proliferation and differentiation of blood and lymphoid cells. However, c-myb is also expressed in various other tissues including epithelia of the gut, lung, skin, mammary glands, and cancers thereof (Queva et al., 1992; Ramsay et al., 1992; Sitzmann et al., 1995; Torelli et al., 1987) . Furthermore, a virus that produces a carboxy-terminal truncation of c-Myb has been reported to cause relatively long latency sarcomas in chickens (Press et al., 1994) . In addition, a 20 residue amino terminal deletion of c-Myb similar to that caused by retroviral insertional mutagenesis in chicken B cell lymphomas can cause epithelial carcinomas and sarcomas as well as lymphomas in chickens (Jiang et al., 1997) . Therefore, it seems more likely that the narrow celltype speci®city of v-myb observed with AMV and the E26 virus may be due to the speci®c mutations present in these viral oncogenes rather than representing a limited potential of the c-myb proto-oncogene itself.
It is clear that both v-Myb and c-Myb can activate the transcription of reporter genes in both animal cells and yeast (see above). Several studies of deletion, linker insertion, and substitution mutants of v-Myb pointed toward a strong correlation between transcriptional activation and oncogenic transformation (Fu and Lipsick, 1996; Grasser et al., 1992; Ibanez and Lipsick, 1990; Lane et al., 1990) . However, more recent studies have called this conclusion into question. First, some mutants of v-Myb that are quite competent for transcriptional activation are incapable of oncogenic transformation (Chen et al., 1995) . Second, the highly leukemogenic v-Myb protein of AMV that contains gag-and env-encoded termini is an extremely weak transcriptional activator (Engelke et al., 1995) . Third, the amino acid substitutions in v-Myb accumulated during the repeated passage of AMV in animals increase the transforming eciency of the protein but decrease its ability to activate transcription (Dini et al., 1995) . Indeed, the most intensely studied Myb-regulated gene, mim-1, is activated by c-Myb and by the E26 Gag-Myb-Ets fusion proteins but not by AMV v-Myb (Ness et al., 1989; Queva et al., 1992) . Notably, the ability of AMV v-Myb to activate mim-1 reporter genes in transient transfection assays does not accurately re¯ect the regulation of the endogenous gene.
Because v-Myb and c-Myb can act as transcriptional repressors as well as transcriptional activators (Ganter and Lipsick, 1997; Mizuguchi et al., 1995; Nakagoshi et al., 1989) , these results raise the question of whether repression rather than activation of speci®c cellular genes might be critical for oncogenic transformation.
In this regard, it has been shown that transcriptional activation by the v-Myb protein increases when transformed cells are induced to terminally differentiate by treatment with phorbol esters (Ganter et al., 1998) . Interestingly, many of the putative`target' genes positively regulated by c-Myb (such as mim-1, CD4, CD13, and the d-and g-TCR genes; reviewed in Ness, (1996) ) appear to be turned on during the differentiation of hematolymphoid cells, but the maintenance of their expression does not appear to require the continued presence of c-Myb (Queva et al., 1992) . These observations suggest a model in which c-Myb has two functions one to drive proliferation of progenitor cells and a second to permit the activation of genes required for terminal dierentiation (Dini and Lipsick, 1993) . v-Myb and other oncogenically activated forms of c-Myb would then cause transformation by carrying out the ®rst but not the second function of normal c-Myb. v-Myb does not appear to function solely as a dominant inhibitor of c-Myb, because endogenous c-Myb is generally not expressed in cells transformed by v-Myb or activated forms of cMyb (Lipsick, 1987) . Conversely, the expression of exogenous c-Myb is compatible with the rapid growth of v-Myb-transformed monoblasts (Smarda and Lipsick, 1994) . These results suggest that v-Myb is oncogenically dominant with respect to c-Myb when both proteins are present in the same cell.
One interesting exception to this model is the ability of v-Myb to activate an autocrine loop of cMGF production that speci®cally requires the amino acid substitutions found in AMV (Dini et al., 1995) . This occurs by a two-step pathway in which AMV v-Myb activates the transcription of the GBX2 gene that encodes a homeodomain protein that in turn directly activates the cMGF gene (Kowenz-Leutz et al., 1997) . This activation of GBX2 requires speci®c amino acid substitutions found in AMV v-Myb. c-Myb itself can activate the GBX2 gene as well, but only in conjunction with other intracellular signaling pathways involving tyrosine kinases and/or Ras. These results suggest an additional wrinkle in which speci®c mutations in AMV v-Myb have been selected to activate speci®c downstream genes that are not normally activated by c-Myb alone. However, v-Myb-like proteins lacking these substitutions still transform myelomonocytic cells quite eciently in cell culture even in the absence of exogenous growth factors (Dini et al., 1995) . The E26 Gag-Myb-Ets protein has been reported to directly regulate the Bcl-2 anti-apoptotic gene, but the ability of AMV v-Myb to regulate this gene remains unclear .
To date much of the work on v-Myb and c-Myb function has focused on transcriptional regulation. However, an alternative mechanism of oncogenesis that remains to be considered is a more direct role of the Myb proteins in cell cycle progression. Three mybrelated genes have been identi®ed in vertebrates thus far, c-myb, A-myb, and B-myb (Nomura et al., 1988) . The ®rst two are tissue-speci®c and are capable of strong transcriptional activation in various cell types. In contrast, B-myb is ubiquitously expressed and has generally been found to activate transcription weakly and only in speci®c cell types or following the introduction of exogenous cyclin A. B-myb itself appears to be a direct target of transcriptional regulation by the cyclinD/Rb/E2F axis (reviewed in Saville and Watson, 1998) . Similarly regulated genes encode DNA polymerase, PCNA, and many enzymes required to produce adequate pools of nucleotides for S phase (DeGregori et al., 1995; Hurford et al., 1997) . The very short half-life of the Myb proteins suggests that they are likely to be produced at a time during the cell cycle shortly before their function is required. Therefore, one wonders whether the ancient function of Myb that is conserved among all of these proteins might be to advance cells through S phase. The transcriptional activation function appears to be a later development that was acquired during the duplication and evolution of A-myb and c-myb that serves a tissue-speci®c rather than a general purpose (Ganter and Lipsick, 1999) . Oncogenic transformation by v-Myb might therefore result from a loss of the more recently acquired strong transcriptional activation function of c-Myb that is essential for terminal dierentiation of speci®c cell types, but a preservation of the more ancient cell cycle regulatory function present in all the Myb proteins.
